Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
Background Relapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-
mediated chemo-immunotherapy has a notable anti-tumor activity in patients with …
mediated chemo-immunotherapy has a notable anti-tumor activity in patients with …
Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory …
G Fathpour, E Jafari, A Hashemi, H Dadgar… - Clinical Nuclear …, 2021 - journals.lww.com
Background Recent evidence has demonstrated high expression of somatostatin receptors
in neuroblastoma (NB) cells. Because of this, we endeavored to evaluate the diagnostic …
in neuroblastoma (NB) cells. Because of this, we endeavored to evaluate the diagnostic …
Efficacy and safety of 124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or neuroblastoma
I Maric, M Weber, A Prochnow, J Schmitz… - Journal of Nuclear …, 2023 - Soc Nuclear Med
We aim to evaluate the efficacy and safety of 124I-metaiodobenzylguanidine (MIBG)
dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or …
dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or …
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and …
R Kuroda, H Wakabayashi, R Araki, A Inaki… - European Journal of …, 2022 - Springer
Purpose Paediatric high-risk neuroblastoma has poor prognosis despite modern
multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting …
multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting …
Verfahren und Techniken bei Phäochromozytomen und Paragangliomen
GB Coura-Filho, M Torres Silva de Oliveira… - … : Diagnose und Therapie, 2024 - Springer
Phäochromozytome sind Tumoren aus Nebennieren oder dem extraadrenalen
sympathischen Nervensystem, während Paragangliome aus pluripotenten Neuralleisten …
sympathischen Nervensystem, während Paragangliome aus pluripotenten Neuralleisten …
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and …
K Rie, H Wakabayashi, A Raita, I Anri… - … Journal of Nuclear …, 2022 - search.proquest.com
Purpose Paediatric high-risk neuroblastoma has poor prognosis despite modern
multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting …
multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting …
Efetividade da radioiodoterapia com 131I-metaiodobenzilguanidina (131I-MIBG) para o tratamento do neuroblastoma
RCL da Silva, CRL da Silva… - Research, Society and …, 2023 - rsdjournal.org
Objective: To assess whether radioiodine therapy with 131 I-metaiodobenzylguanidine (131
I-mIBG) increases the survival of patients diagnosed with neuroblastoma, avid-mIBG …
I-mIBG) increases the survival of patients diagnosed with neuroblastoma, avid-mIBG …
Procedures and Techniques in Pheochromocytomas and Paragangliomas
GB Coura-Filho, M Torres Silva de Oliveira… - Nuclear Medicine in …, 2022 - Springer
Pheochromocytomas are tumors from adrenal glands or extra-adrenal sympathetic nervous
system, while paragangliomas originate from pluripotent neural crest stem cells and nuclear …
system, while paragangliomas originate from pluripotent neural crest stem cells and nuclear …
Theranostics in Japan
S Kinuya - The Evolution of Radionanotargeting towards Clinical …, 2022 - books.google.com
Frankly, Japan is at the end of the line of current clinical theranostics such as PRRT and
PSMA. Many patients go abroad for PRRT and PSMA treatment. This lamentable situation …
PSMA. Many patients go abroad for PRRT and PSMA treatment. This lamentable situation …
What is 核医学治療?
絹谷清剛 - 日本小児放射線学会雑誌, 2024 - jstage.jst.go.jp
要旨 核医学治療とは, 標的組織に発現する分子に特異的結合する物質を放射標識し,
組織集積させることにより細胞死を惹起させるものである. 古くには, 放射性ヨウ素 131 I …
組織集積させることにより細胞死を惹起させるものである. 古くには, 放射性ヨウ素 131 I …